- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00407576
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
June 30, 2017 updated by: National Institute of Mental Health (NIMH)
Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid.
The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called [11C]MeS-IMPY.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid plaques in brain.
A substantial body of research indicates that the presence of increased beta -amyloid peptide is neurotoxic, and may initiate further pathology observed in AD including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration.
There are multiple binding sites available on beta-amyloid plaques.
Three clearly identified sites are Congo-red type, Thioflavin-T type, and FDDNP type.
Radioligands currently under development using positron emission tomography (PET) for studying beta-amyloid in clinical research or drug development are based on Thioflavin-T site, such as [11C]PIB and [11C]SB-13.
Though variously effective, these radioligands have one or more drawbacks with respect to measuring relative regional beta-amyloid densities.
Therefore, we have recently developed [11C]MeS-IMPY as an alternative radioligand for imaging beta-amyloid, which will allow a more accurate quantification of amyloid plaques in AD brain.
In the current protocol, we wish to evaluate [11C]MeS-IMPY in both healthy subjects and AD patients to determine the kinetics of brain imaging beta-amyloid plaques in AD patients.
Study Type
Interventional
Enrollment
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
- INCLUSION CRITERIA:
Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests.
Informed Consent.
AD Patients: Mini-Mental State Examination (score greater than or equal to 10).
AD Patients: Meet NINCDS-ADRDA criteria for probable AD.
EXCLUSION CRITERIA:
- Current or prior history of any alcohol or drug abuse.
- Severe systemic disease based on history and physical exam.
- Positive result on urine screen for illicit drugs.
- Laboratory tests with clinically significant abnormalities.
- Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
- Pregnancy or breast feeding.
- Claustrophobia.
- Presence of ferromagnetic metal in the body or heart pacemaker.
- History of brain disease other than Alzheimer's disease.
- Unable to lay on one's back for the PET/MRI scan.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001 Dec 15;21(24):RC189. doi: 10.1523/JNEUROSCI.21-24-j0004.2001.
- Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997 Nov;38(11):1818-23.
- Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002 Oct;22(10):1271-81. doi: 10.1097/01.WCB.0000038000.34930.4E.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
November 7, 2008
Study Registration Dates
First Submitted
December 2, 2006
First Submitted That Met QC Criteria
December 2, 2006
First Posted (Estimate)
December 5, 2006
Study Record Updates
Last Update Posted (Actual)
July 2, 2017
Last Update Submitted That Met QC Criteria
June 30, 2017
Last Verified
November 7, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 070036
- 07-M-0036
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on [11C]MeS-IMPY
-
Institute for Neurodegenerative DisordersAlzheimer's Association; Molecular NeuroImagingCompletedAlzheimer DiseaseUnited States
-
The University of Texas Health Science Center at...Completed
-
National Institute of Mental Health (NIMH)CompletedEvaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Mood DisordersBipolar Disorder | Unipolar Depression | Mood DisorderUnited States
-
Centro Hospitalar De São João, E.P.E.University of Padova; Clinical Hospital Centre Zagreb; University of Giessen; University...CompletedEmbolism | Atrial Fibrillation | Infarction, BrainPortugal
-
Columbia UniversityRecruitingNeurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer DiseaseUnited States
-
National Institute of Mental Health (NIMH)TerminatedDementiaUnited States
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States
-
Columbia UniversityCompleted
-
Wendell Yap, MDUniversity of Kansas Medical CenterNo longer availableProstate CancerUnited States
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States